Earnings summaries and quarterly performance for IN8BIO.
Executive leadership at IN8BIO.
Board of directors at IN8BIO.
Research analysts covering IN8BIO.
Recent press releases and 8-K filings for INAB.
IN8bio Provides Glioblastoma Clinical Data Update and Financial Outlook
INAB
Guidance Update
New Projects/Investments
- IN8bio reported updated Phase I data for its INB-200/INB-400 glioblastoma program, demonstrating a median progression-free survival of 13 months and a median overall survival of 17.2 months as of December 2025 for repeat-dose patients, significantly exceeding the control arm's 6.6 months PFS and 13.2 months OS. The company plans to seek FDA guidance on a potential registrational path forward and expects to provide an update to investors later this summer.
- The company introduced INB-619, a novel CD19-targeting T cell engager, which has shown high potency with an EC50 of 36 picomolar and a wide therapeutic window with significantly reduced cytokine release syndrome (CRS) markers compared to commercial B-cell depleters.
- IN8bio recently completed a $20.1 million financing round, providing capital through the first half of 2027. An additional $20.1 million tranche will be triggered by positive mouse data for INB-619, extending the financial runway through 2027.
- Key upcoming milestones include the presentation of INB-619 mouse data by late summer and updated INB-100 leukemia data at a medical meeting late this year.
3 hours ago
IN8bio Provides Update on Clinical Programs and Financing
INAB
New Projects/Investments
Guidance Update
- IN8bio is focused on developing cellular therapies using gamma delta T cells, with programs including INB-100 for leukemia, INB-200/INB-400 for glioblastoma, and a new T cell engager platform, INB-619, for oncology and autoimmune diseases.
- In its glioblastoma program (INB-200/INB-400), repeat dose patients achieved a median progression-free survival of 13 months and a median overall survival of 17.2 months as of December 2025, with no major toxicity signals. The company plans to seek FDA guidance on a potential registrational path.
- IN8bio recently completed a financing round, raising $20.1 million, which provides capital into the first half of 2027. An additional $20.1 million tranche will be triggered by mouse data for the INB-619 T-cell engager, extending the runway through 2027.
- Key upcoming milestones for 2026 include FDA guidance on the glioblastoma program, mouse data for the INB-619 T-cell engager by late summer, and updated Phase 1 data for the INB-100 leukemia program by late year.
4 hours ago
IN8bio Highlights Clinical Progress and Financial Runway
INAB
New Projects/Investments
Guidance Update
- IN8bio (INAB) presented updated data for its INB-200/INB-400 glioblastoma program, showing a median progression-free survival of 13 months for repeat dose patients compared to 6.6 months for the control arm, and a median overall survival of 17.2 months (as of December 2025) versus 13.2 months for the control arm. The company plans to seek FDA guidance on a potential registrational path forward.
- The company introduced INB-619, a novel CD19-targeting T cell engager, which demonstrated high potency and a significantly wider therapeutic window with reduced cytokine release syndrome compared to commercial B-cell depleters in preclinical studies. Mouse data for INB-619 is anticipated by late summer 2026.
- IN8bio recently completed a $20.1 million financing round, extending its cash runway into the first half of 2027. An additional $20.1 million tranche is expected to be triggered by the INB-619 mouse data, which would further extend the runway through 2027.
- Key upcoming milestones include completing enrollment and dosing for the INB-100 leukemia program near term, with updated Phase 1 data expected late 2026.
4 hours ago
IntraBio Receives European Commission Approval for AQNEURSA® to Treat Niemann-Pick Disease Type C
INAB
Product Launch
- The European Commission has granted marketing authorization for AQNEURSA® (Levacetylleucin) for the treatment of neurological symptoms of Niemann-Pick disease Type C (NPC) in adults and children aged 6 years and older, weighing at least 20 kg.
- This approval, which follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), is based on a Phase III study demonstrating a statistically significant and clinically relevant improvement in neurological symptoms and function after 12 weeks.
- Long-term data from an open-label extension phase showed sustained improvements and a 118% reduction in annual disease progression after one year.
- AQNEURSA® is also approved in the United States for NPC patients weighing ≥ 15 kg.
Jan 21, 2026, 11:19 PM
IN8bio Presents Updated Phase 1/2 Clinical Data for Glioblastoma Treatment
INAB
New Projects/Investments
- IN8bio reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials for newly diagnosed glioblastoma (GBM).
- Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months for the standard-of-care (SOC) control group (+97%).
- Median overall survival (mOS) for DeltEx™ DRI patients is currently 17.2+ months and rising as of December 31, 2025, compared to 13.2 months for SOC (+30.3%), with the treatment demonstrating a well-tolerated safety profile.
- The company plans to discuss potential clinical pathways, including accelerated approval, with the FDA, supported by funds from recent financing.
Jan 12, 2026, 1:00 PM
IN8bio Announces $20.1 Million Private Placement with Conditional Second Tranche
INAB
- IN8bio, Inc. entered into a Securities Purchase Agreement on December 18, 2025, for a private placement of common stock and pre-funded warrants.
- The Initial Closing, anticipated around December 22, 2025, is expected to generate approximately $20.1 million in gross proceeds from the sale of 5,127,029 shares of common stock at $1.38 per share and pre-funded warrants for up to 9,452,677 warrant shares at $1.3799 per pre-funded warrant.
- A Second Closing, potentially raising an additional $20.1 million, is conditional on achieving the INB-619 Milestone (animal model data presentation) by December 31, 2026, and meeting a specified stock price threshold or receiving an investor waiver.
- The company also signed a Registration Rights Agreement on December 18, 2025, committing to register the issued securities for resale within 30 days of each closing, with a target effectiveness within 90 days if reviewed by the SEC.
Dec 19, 2025, 10:22 PM
IN8bio Announces Private Placement of up to $40.2 Million
INAB
New Projects/Investments
- IN8bio announced a private placement to raise up to approximately $40.2 million in gross proceeds.
- The initial closing, expected around December 22, 2025, will provide approximately $20.1 million and is projected to extend the company's cash runway into the first half of 2027.
- Funds will primarily advance INB-619, a novel gamma-delta T cell engager, through Investigational New Drug (IND) enabling studies for oncology and autoimmune diseases.
- The financing was led by Coastlands Capital, with participation from other institutional investors and company insiders.
Dec 19, 2025, 1:00 PM
IN8bio, Inc. Reports Q3 2025 Financial Results and Business Highlights
INAB
Earnings
New Projects/Investments
- IN8bio, Inc. reported a net loss of $3.9 million, or $0.85 per basic and diluted common share, for the third quarter ended September 30, 2025, an improvement from a net loss of $7.1 million, or $4.49 per share, in the comparable prior year period.
- As of September 30, 2025, the company's cash position was $10.7 million, significantly up from $4.0 million as of September 30, 2024.
- Research and Development (R&D) expenses for the three months ended September 30, 2025, were $2.1 million, a decrease from $3.3 million in the comparable prior year period, primarily due to a strategic pause on the INB-400 program and personnel-related costs.
- The company presented new preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating potent B cell depletion with minimal cytokine release, and expanded its Phase 1 INB-100 trial to accelerate patient enrollment.
- Upcoming milestones include updated Phase 1 and 2 data for the INB-200/400 program in glioblastoma at the SNO Annual Meeting (November 19-23, 2025) and additional preclinical data for INB-619 at the ASH Annual Meeting (December 6-9, 2025).
Nov 6, 2025, 9:01 PM
IN8bio Reports Third Quarter 2025 Financial Results and Business Highlights
INAB
Earnings
New Projects/Investments
- IN8bio reported a net loss of $3.9 million, or $0.85 per share, for the third quarter ended September 30, 2025, an improvement from a net loss of $7.1 million, or $4.49 per share, in the comparable prior year period. The company's cash position as of September 30, 2025, was $10.7 million, compared to $4.0 million as of September 30, 2024.
- The company presented new preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating equivalent potency to FDA-approved commercial products in achieving deep B cell depletion with minimal adverse cytokine release.
- IN8bio expanded its Phase 1 INB-100 clinical trial to The Ohio State University, aiming to accelerate patient enrollment.
- Upcoming milestones include presenting updated Phase 1 and 2 data from the INB-200/400 program in glioblastoma at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting and additional preclinical data for INB-619 in oncology at the 2025 American Society of Hematology (ASH) Annual Meeting.
Nov 6, 2025, 9:00 PM
IN8bio expands INB-100 Phase 1 clinical trial
INAB
New Projects/Investments
- IN8bio, Inc. has added The Ohio State University as a new clinical site for its ongoing Phase 1 trial of INB-100.
- The INB-100 therapy is a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation.
- The addition of the new site is expected to accelerate enrollment and complete the Phase 1 trial, with follow-up data anticipated next year.
- INB-100 has shown encouraging long-term survival outcomes, with the earliest treated patients now beyond four- and five-years relapse-free.
Oct 29, 2025, 12:00 PM
Fintool News
In-depth analysis and coverage of IN8BIO.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more